Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

PRINCETON, N.J., November 05, 2024--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in two upcoming investor conferences in November 2024. Samit ...

In a welcome move, Bristol Myers Squibb saw its Relative Strength Rating improve from 70 to 76 on Tuesday. Please watch the video at Investors.com - Stock Market Exposure: How To Make Incremental ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

David Risinger, an analyst from Leerink Partners, maintained the Hold rating on Bristol-Myers Squibb (BMY – Research Report). The associated price target was raised to $55.00. David Risinger has given ...

Some people who took a new schizophrenia drug for one year improved with only a few side effects, but many dropped out of the ...

On Friday, Bristol-Myers Squibb Co (BMY) stock saw a decline, ending the day at $54.32 which represents a decrease of $-1.45 or -2.60% from the prior close of $55.77. The stock opened at $55.88 and ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Bristol-Myers Squibb (BMY – Research Report) and Envista ...

Bristol Myers Squibb Q3 revenue rose 8% YoY to $11.89 billion, driven by strong Growth Portfolio sales, especially Eliquis.

Bristol Myers Squibb's (BMY) new schizophrenia drug, Cobenfy, improves symptoms with a well-tolerated safety profile in two ...

Princeton, N.J.-based Bristol Myers BMY had net income of $1.2 billion, or 60 cents a share, in the quarter, down from $1.9 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...